Age-related Vision Dysfunction Market

• The Age-related Vision Dysfunction Market Size is anticipated to grow with a CAGR during the study period (2020-2034).
• The dynamics of Age-related Vision Dysfunction market is anticipated to change in the coming years owing to the improvement in the diagnostic methodologies, raising awareness of the disease, increasing healthcare expenditures globally, and the expected launch of emerging therapies during the forecast period.
• Label expansion into other kinds of indications is also very much on the cards if the drug approved in one indications is able to show a similar kind of efficacy. E.g., EYLEA was first approved by the FDA for Wet Age-related Macular Degeneration and later the label was expanded for Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR).
• Currently, b stand as the cornerstone of emerging and marketed drug options for Age-related vision dysfunction, particularly in the treatment of conditions such as Age-related macular degeneration and diabetic retinopathy.
• In March 2025, Luxa Biotechnology LLC (Luxa), a clinical-stage biotech company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), has released clinical data from its Phase 1/2a trial. The study evaluates RPESC-RPE-4W, Luxa’s proprietary retinal pigment epithelium (RPE) cell therapy, in patients with dry AMD.
• In December 2024, Galimedix Therapeutics has initiated its Phase II eDREAM clinical trial to assess the safety and efficacy of GAL-101 eye drops in patients with dry age-related macular degeneration.
• In December 2024, Ocugen, Inc. announced that the Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial has convened and authorized progression to the second phase of the Phase 1/2 study. OCU410 (AAV5-hRORA) is a novel modifier gene therapy under development aimed at treating geographic atrophy (GA) linked to dry age-related macular degeneration (dAMD).
• In February 2024, Outlook Therapeutics mentioned that the resubmission of the ONS-5010 BLA is expected by the end of calendar year 2024. Moreover, in March 2024, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration in the EU.
• In November 2023, Kodiak sciences announces first time presentation of primary endpoint data from tarcocimab tedromer Phase III glow study in patients with diabetic retinopathy at American academy of ophthalmology annual meeting.
• In April 2023, Allegro Ophthalmics received an agreement from the United States Food and Drug Administration (US FDA) under a Special Protocol Assessment (SPA) for the design of its Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative Age-related macular degeneration (dry AMD).

DelveInsight's "Age-related Vision Dysfunction Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Age-related Vision Dysfunction market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Age-related Vision Dysfunction market size from 2020 to 2034. The report also covers current Age-related Vision Dysfunction treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Age-related Vision Dysfunction Disease Understanding

Age-related Vision Dysfunction Overview, Country-Specific Treatment Guidelines and Diagnosis

Age-related Vision Dysfunction presents a significant challenge among the elderly population, with a staggering one in three individuals experiencing some form of vision-reducing eye disease by the age of 65. This spectrum of conditions encompasses a variety of ailments, including Age-related macular degeneration, glaucoma, cataracts, diabetic retinopathy, and refractive errors like myopia and presbyopia. These conditions not only compromise the quality of life but also pose serious risks of permanent vision loss if left untreated. Hence, early detection and comprehensive management are paramount in mitigating their impact on elderly individuals.

Diagnosing Age-related Vision Dysfunction requires a multifaceted approach involving thorough clinical evaluations and specialized testing procedures. A comprehensive dilated eye exam serves as the cornerstone for detecting many of these conditions, enabling healthcare professionals to assess the health of the retina and optic nerve. Additional diagnostic modalities, such as visual acuity tests, slit-lamp examinations, retinal exams, and imaging techniques like fluorescein angiography and optical coherence tomography, play crucial roles in confirming diagnoses and guiding treatment decisions.

The Age-related Vision Dysfunction report  provide overview of Age-related Vision Dysfunction pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Further details related to country-based variations in diagnosis are provided in the report...

Age-related Vision Dysfunction Treatment

The treatment of Age-related Vision Dysfunction depends on the cause or the disease type. Both pharmacological and non-pharmacological treatment options are available.

There is no cure, but treatment for Age-related macular degeneration may slow the disease and keep the patient away from having a severe loss of vision. Treatment options include anti-angiogenic drugs, laser therapy, and photodynamic laser therapy. The US FDA also approved BYOOVIZ (ranibizumab-nuna) as the first biosimilar to LUCENTIS (ranibizumab injection) for the treatment of several eye diseases and conditions, including neovascular (wet) Age-related macular degeneration, a leading cause of vision loss and blindness for Americans aged 65 years and older. Anti-Vascular endothelial growth factor drugs or drug-releasing implants that are FDA-approved for injection into the eye for treatment of Diabetic Macular Edema in the United States include: ILUVIEN (Alimera Science), OZURDEX (Allergan), LUCENTIS (Genentech), and Regeneron’s EYLEA has gained an FDA nod for the infant version of the disorder.

Further details related to treatment are provided in the report...

Age-related Vision Dysfunction Epidemiology

The Age-related Vision Dysfunction epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034. The Age-related Vision Dysfunction epidemiology is segmented with detailed insights into total Prevalent Cases of Age-related Vision Dysfunction, total Diagnosed Prevalent Cases of Age-related Vision Dysfunction, Type-specific Diagnosed Prevalent Cases of Age-related Vision Dysfunction, Severity-specific Diagnosed Prevalent Cases of Age-related Vision Dysfunction, and total Treatable Cases of Age-related Vision Dysfunction.

The epidemiology of Age-related vision dysfunctions is based on the primary etiologies of the disease based on the prevalent population being affected in specific countries. The indications involve Wet Age-related Macular Degeneration, Cataract, Glaucoma, Presbyopia, and Diabetic Retinopathy. The number of prevalent cases of Age-related vision dysfunction is further segmented into diagnosed cases, severity-specific cases, and the treated patient pool of Age-related vision dysfunction.

Key Findings:

• As per DelveInsight estimates, the cases of presbyopia are the highest among all the considered etiologies of in the 7MM.
• The United States accounted for more than 35% of cases of Wet-Age-related Macular Degeneration in the 7MM.
• The United States accounted for the highest prevalent cases of Glaucoma in the year 2023.
• As per DelveInsight estimates, Japan accounted for 50% of total Diagnosed prevalent cases of Presbyopia in 2023.

Recent Developments In The Age-related Vision Dysfunction Market Landscape:

• In March 2025, Luxa Biotechnology LLC (Luxa), a clinical-stage biotech company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), has released clinical data from its Phase 1/2a trial. The study evaluates RPESC-RPE-4W, Luxa’s proprietary retinal pigment epithelium (RPE) cell therapy, in patients with dry AMD.
• In December 2024, Galimedix Therapeutics has initiated its Phase II eDREAM clinical trial to assess the safety and efficacy of GAL-101 eye drops in patients with dry age-related macular degeneration.
• In December 2024, Ocugen, Inc. announced that the Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial has convened and authorized progression to the second phase of the Phase 1/2 study. OCU410 (AAV5-hRORA) is a novel modifier gene therapy under development aimed at treating geographic atrophy (GA) linked to dry age-related macular degeneration (dAMD).
• In February 2024, Outlook Therapeutics mentioned that the resubmission of the ONS-5010 BLA is expected by the end of calendar year 2024. Moreover, in March 2024, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration in the EU.
• In November 2023, Kodiak sciences announces first time presentation of primary endpoint data from tarcocimab tedromer Phase III glow study in patients with diabetic retinopathy at American academy of ophthalmology annual meeting.
• In April 2023, Allegro Ophthalmics received an agreement from the United States Food and Drug Administration (US FDA) under a Special Protocol Assessment (SPA) for the design of its Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative Age-related macular degeneration (dry AMD).

Age-related Vision Dysfunction Drug Analysis

The drug chapter segment of the Age-related Vision Dysfunction report encloses a detailed analysis of Age-related Vision Dysfunction marketed drugs and late-stage (Phase III and Phase II) Age-related Vision Dysfunction pipeline drugs. It also deep dives into the Age-related Vision Dysfunction pivotal clinical trial details; recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Marketed Age-related Vision Dysfunction Drugs

VABYSMO: Genentech

VABYSMO (faricimab-svoa) is a prescription medicine, developed by Genentech, given by injection into the eye used to treat adults with neovascular (wet) Age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. VABYSMO was first approved in the US by the FDA in January 2022, targets and inhibits two disease pathways that drive wet Age-related macular degeneration and diabetic macular edema and is now available in multiple countries, including Europe.  In October 2023, Roche received a new indication approval by FDA for the use of VABYSMO to treat macular edema following retinal vein occlusion.

LUCENTIS: Genentech

LUCENTIS (ranibizumab injection) is a prescription medicine, developed by Genentech for the treatment of patients with wet Age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization. In April 2017, FDA Approves Genentech’s LUCENTIS (ranibizumab Injection) for Diabetic Retinopathy, the leading cause of blindness among working age adults in the United States. It was the first and only medicine FDA-approved to treat all forms of diabetic retinopathy and Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of Health (NIH)-funded collaborative group study.

Note: Detailed current therapies assessment will be provided in the full report of Age-related Vision Dysfunction

Emerging Age-related Vision Dysfunction Drugs

KSI-301 (tarcocimab tedromer): Kodiak Sciences Inc.

Kodiak Science’s KSI-301 is a novel anti-Vascular endothelial growth factor biologic designed to rapidly inhibit Vascular endothelial growth factor and provide extended durability of action to reduce the burden of frequent anti-Vascular endothelial growth factor injections. Delivering potent and sustained vascular endothelial growth factor inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. The drug has recently completed its phase III study. The biologic is also in Phase III for Diabetic Macular Edema, Diabetic retinopathy, Tetinal Vein Occlusion, and Triplet Inhibitor for dry Age-related Macular Degeneration. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of vascular endothelial growth factor for up to 6 months.

ONS-5010/LYTENAVA: Outlook Therapeutics

Outlook Therapeutics' ONS-5010/LYTENAVA is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet Age-related Macular Degeneration and other retinal diseases. ONS-5010 is a full-length, humanized anti-Vascular endothelial growth factor recombinant monoclonal antibody (mAb) that inhibits vascular endothelial growth factor and associated angiogenic activity. In February 2024, the company mentioned that the resubmission of the ONS-5010 BLA is expected by the end of calendar year 2024. Moreover, in March 2024, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration in the EU.

Note: Detailed emerging therapies assessment will be provided in the final report.

Age-related Vision Dysfunction Market Outlook

The Age-related Vision Dysfunction market outlook reflects a dynamic landscape characterized by a growing demand for innovative treatments and technologies to address the diverse needs of aging populations worldwide. With approximately one in three individuals experiencing some form of vision-reducing eye disease by the age of 65, the prevalence of conditions such as Age-related macular degeneration, glaucoma, cataracts, diabetic retinopathy, and refractive errors underscores the urgent need for effective therapeutic interventions.

The advent of anti-angiogenic drugs, such as BYOOVIZ (ranibizumab-nuna), and innovative therapies like VABYSMO for wet Age-related Macular Degeneration signifies a paradigm shift in the management of retinal diseases, offering patients new hope for preserving vision and improving quality of life. Similarly, advancements in glaucoma treatment modalities, including minimally invasive glaucoma surgery (MIGS) and novel intraocular pressure-lowering medications are reshaping the therapeutic landscape by providing more personalized and targeted approaches to disease management. Furthermore, the emergence of refractive surgery techniques like LASIK and lens implantation procedures underscores the growing demand for refractive error correction among aging populations seeking to maintain visual acuity and independence.

Age-related Vision Dysfunction companies, such as Outlook Therapeutics, Kodiak Sciences, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Age-related Vision Dysfunction.

• The United States accounted for the highest Age-related Vision Dysfunction market size in 2023.
• KSI-301, ONS-5010 / LYTENAVA, and EYP-1901 are the most anticipated emerging therapies/products that are awaiting approval and are expected to increase the Age-related Vision Dysfunction market size.
• The rise in the geriatric population among 7MM countries is one of the major reasons for the increase in the prevalence of Age-related Vision Dysfunction. These factors along with the expected launch of emerging therapies will boost the Age-related Vision Dysfunction market in the forecasted period.

Age-related Vision Dysfunction Drugs Uptake

This section focuses on the uptake rate of potential Age-related Vision Dysfunction drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Further detailed analysis of emerging therapies drug uptake in the report...

Age-related Vision Dysfunction Pipeline Activities

The Age-related Vision Dysfunction pipeline report provides insights into Age-related Vision Dysfunction clinical trials within Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics. 

 Age-related Vision Dysfunction Pipeline Development Activities

The Age-related Vision Dysfunction clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Age-related Vision Dysfunction emerging therapies. 

KOL Views on Age-related Vision Dysfunction

To keep up with the real-world scenario in current and emerging Age-related Vision Dysfunction market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Harvard Medical School Department of Ophthalmology, American Optometric Association etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of Age-related Vision Dysfunction. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

KOL Views

“Diastolic blood pressures and mean arterial blood pressures positively correlated with an increased risk of early Age-related Macular Degeneration even after controlling for age. Although the relationship between blood pressure and Age-related Macular Degeneration is not always consistent, several studies have demonstrated an association.”

“The dry form of Age-related macular degeneration is common, affecting approximately 80% of people with Age-related Macular Degeneration; there is a huge unmet need for treatment for these patients.”

Age-related Vision Dysfunction Report Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging Age-related Vision Dysfunction therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Age-related Vision Dysfunction Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. In addition, Medicare and Medicaid are the largest government funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), third party organizations that provide services, educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Age-related Vision Dysfunction Market Report

• The Age-related Vision Dysfunction market report covers a segment of key events, an executive summary, descriptive overview of Age-related Vision Dysfunction, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging Age-related Vision Dysfunction therapies, along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape.
• A detailed review of the Age-related Vision Dysfunction market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Age-related Vision Dysfunction market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Age-related Vision Dysfunction market.

Age-related Vision Dysfunction Market Report Insights

• Age-related Vision Dysfunction Patient Population
• Age-related Vision Dysfunction  Therapeutic Approaches
• Age-related Vision Dysfunction Pipeline Analysis
• Age-related Vision Dysfunction Market Size
• Age-related Vision Dysfunction Market Trends
• Existing and future Age-related Vision Dysfunction Market Opportunity

Age-related Vision Dysfunction Market Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Age-related Vision Dysfunction Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging Age-related Vision Dysfunction therapies
• Key Cross Competition
• Conjoint analysis
• Age-related Vision Dysfunction Drugs Uptake
• Key Age-related Vision Dysfunction Market Forecast Assumptions

Age-related Vision Dysfunction Market Report Assessment

• Current Age-related Vision Dysfunction Treatment Practices
• Age-related Vision Dysfunction Unmet Needs
• Age-related Vision Dysfunction Pipeline Product Profiles
• Age-related Vision Dysfunction Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Age-related Vision Dysfunction Market Drivers
• Age-related Vision Dysfunction Market Barriers

FAQs

• What is the growth rate of the 7MM Age-related Vision Dysfunction treatment market?
• What was the Age-related Vision Dysfunction market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label Age-related Vision Dysfunction therapies?
• What are the current and emerging options for the treatment of Age-related Vision Dysfunction?
• How many companies are developing therapies for the treatment of Age-related Vision Dysfunction?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing Age-related Vision Dysfunction therapies?
• What is the acceptability of preferred treatment options among patients and physicians in real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved Age-related Vision Dysfunction therapies?

Reasons to buy Age-related Vision Dysfunction Market Forecast Report

• The Age-related Vision Dysfunction market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Age-related Vision Dysfunction Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Age-related Vision Dysfunction market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Age-related Vision Dysfunction market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Age-related Vision Dysfunction market so that the upcoming players can strengthen their development and launch strategy.